Johann Bauersachs

Johann Bauersachs
Born (1966-04-22) April 22, 1966
Karlsruhe
Residence Germany
Nationality German
Fields internal medicine, cardiology, intensive care
Institutions Hannover Medical School
Known for acute coronary syndrome, left ventricular healing and remodeling after ischemia as well as acute and chonic heart failure.

Johann Bauersachs (born 22 April 1966 in Karlsruhe) is a German internist, cardiologist, intensive care physician and professor at the Hannover Medical School. He is director of the Department of Cardiology and Angiology. He is known for his scientific work in the fields of acute coronary syndrome, left ventricular healing and remodeling after ischemia as well as acute and chonic heart failure.

Biography

After his studies and medical thesis at the University of Freiburg in 1993 Bauersachs worked as assistant physician at the Department of Medicne IV and at the Institute of Cardiovascular Physiology of the University Hospital Frankfurt, and at the Department of Medicine of the University Medical Centre Mannheim. He was habilitated in internal medicine at the University Hospital of Wuerzburg in 2001 and reiceived the venia legendi. He was appointed associate professor and consultant in cardiology and intensive care at the Department of Medicine at the University Hospital of Wuerzburg in 2008. Since 2010, Bauersachs is full professor and director of the Department of Cardiology and Angiology at Hannover Medical School.

Scientific contribution

Research activities of Bauersachs focused initially on endothelial dependent dilatation which is crucial for the regulation of blood pressure and organ perfusion, and especially the characterisation of nitric oxide (NO) dependent and independent endothelial factors.[1] Supported by research grants from the Deutsche Forschungsgemeinschaft (DFG) ad personam and within special research programs (SFBs 355 und 688 at Wuerzburg University) he investigated endothelial dysfunction in heart failure, and myocardial remodeling after experimental myocardial infarction in rats and mice. He could demonstrate the importance of vascular oxidative stress for abnormal endothelial function in heart failure.[2] His group showed the attenuation of left ventricular remodeling after myocardial infarction by treatment with statins, the mineralocorticoid receptor (MR) antagonist Eplerenone and a novel enhancer of endothelial NO synthase.[3][4][5] The importance of the MR for early healing and remodeling after myocardial infarction was demonstrated by treatment with MR antagonists, but also by cell specific MR deletion.[6][7][8] These research activities were the basis for clinical trials to improve MR antagonist therapy in patients with myocardial infarction, heart failure and renal dysfunction.[9][10]

Together with T. Thum, Bauersachs published research on the role of non-coding RNA, especially microRNA, for cardiovascular diseases,[11][12][13] that also led to several patents. The importance of microRNAs for fetal reprogramming of gene expression in heart failure was demonstrated,[11] as well as the treatment using a so-called Antagomir in a mouse model of heart failure.[12]

These research activities are continued within the DFG cluster of excellence REBIRTH („From Regenerative Biology to Reconstructive Therapy“)[14][15] at Medical School Hannover with special emphasis on translation to clinical application. Bauersachs is chair of two clinical trials funded by the German Ministry of Research and Education (BMBF) in patients with heart failure: the study investigating the efficacy of Bromocriptine on left ventricular function in women with peripartal cardiomyopathy (PPCM)[16][17] and the large endpoint trial DIGIT-HF (DIGitoxin to Improve ouTcomes in patients with advanced chronic systolic Heart Failure; EudraCT No: 2013-005326-38).[18]

Beside his research activities, Bauersachs contributes to science as editor and reviewer for medical and scientific journals, as organiser of meetings and congresses, and as reviewer for international funding institutions, eg the Deutsche Forschungsgemeinschaft (as member of the collegium Medicine since 2012), INSERM (France), ANR (France), Wellcome Trust (UK), the German Heart Foundation, and the EU.

Memberships

Bauersachs is a board member of the Heart Failure Association (HFA) of the European Society of Cardiology[19] and chair of the HFA-Study Group on Peripartum cardiomyopathy. He is a member of the program committees of the German Cardiac Society (DGK) and of the German Society of Internal Medicine (DGIM).[20] Furthermore he is chair of the ESAC Germany[21] as well as one of the coordinators of the COST Action ADMIRE (Aldosterone and Mineralocorticoid Receptor), supported by the European Union.[22] Bauersachs is a member of the editorial boards of Hypertension,[23] Cardiovascular Research, Basic Research in Cardiology[24] as well as Clinical Research in Cardiology.[25] He has been a DFG review board member since 2012. He is a member of the Steering committee and area manager in the excellence cluster REBIRTH (From Regenerative Biology to Reconstructive Therapy).

Honors and awards

Publications

Bauersachs published more than 250 scientific articles (October 2015):

PubMed Johann Bauersachs Publication list

PubFacts Johann Bauersachs Publikationsliste

See also

microRNA

External links

References

  1. ↑ Bauersachs J, Popp R, Hecker M, Sauer E, Fleming I, Busse R. Nitric oxide attenuates the release of endothelium-derived hyperpolarizing factor. Circulation. 1996
  2. ↑ Bauersachs J, Bouloumié A, Fraccarollo D, Hu K, Busse R, Ertl G Endothelial dysfunction in chronic myocardial infarction despite increased vascular endothelial nitric oxide synthase and soluble guanylate cyclase expression: role of enhanced vascular superoxide production. Circulation. 1999 Jul 20;100(3):292-8
  3. ↑ Bauersachs J, Galuppo P, Fraccarollo D, Christ M, Ertl G. Improvement of left ventricular remodeling and function by hydroxymethylglutaryl coenzyme a reductase inhibition with cerivastatin in rats with heart failure after myocardial infarction. Circulation. 2001
  4. ↑ Fraccarollo D, Galuppo P, Hildemann S, Christ M, Ertl G, Bauersachs J. Additive improvement of left ventricular remodeling and neurohormonal activation by aldosterone receptor blockade with eplerenone and ACE inhibition in rats with myocardial infarction. J Am Coll Cardiol. 2003 Nov 5;42(9):1666-73.
  5. ↑ Fraccarollo D, Widder JD, Galuppo P, Thum T, Tsikas D, Hoffmann M, Ruetten H, Ertl G, Bauersachs J (2008). Improvement of left ventricular remodelling by the endothelial nitric oxide synthase enhancer AVE9488 after experimental myocardial infarction. Circulation 118, 818-82.
  6. ↑ Fraccarollo D, Galuppo P, Schraut S, Kneitz S, van Rooijen N, Ertl G, Bauersachs J (2008). Immediate Mineralocorticoid Receptor Blockade After Myocardial Infarction Improves Infarct Healing by Modulation of the Inflammatory Response. Hypertension 51, 1-10
  7. ↑ Thum T, Schmitter K, Fleissner F, Wiebking V, Dietrich B, Widder JD, Jazbutyte V, Hahner S, Ertl G, Bauersachs J (2011). Impairment of endothelial progenitor cell function and vascularization capacity by aldosterone in mice and humans. Eur Heart J 32, 1275-86.
  8. ↑ Fraccarollo D, Berger S, Galuppo P, Kneitz S, Hein L, Schütz G, Frantz S, Ertl G, Bauersachs J (2011). Deletion of cardiomyocyte mineralocorticoid receptor ameliorates adverse remodeling after myocardial infarction. Circulation 123, 400-408.
  9. ↑ Bauersachs J. The ARTS of third-generation mineralocorticoid receptor antagonists: achieving cardiovascular benefit with minimized renal side effects? Eur Heart J. 2013 Aug;34(31):2426-8. doi: 10.1093/eurheartj/eht235
  10. ↑ Bauersachs J, Jaisser F, Toto R (2015). Mineralocorticoid Receptor Activation and Mineralocorticoid Receptor Antagonist Treatment in Cardiac and Renal Diseases. Hypertension 65, 257-263.
  11. 1 2 Thum T, Galuppo P, Wolf C, Fiedler J, Kneitz S, van Laake LW, Doevendans PA, Mummery CL, Borlak J, Haverich A, Gross C, Engelhardt S, Ertl G, Bauersachs J (2007). MicroRNAs in the human heart: A clue to fetal gene reprogramming in heart failure. Circulation 116, 258-267.
  12. 1 2 Thum T, Gross C, Fischer T, Fiedler J, Just S, Rottbauer W, Bussen M, Galuppo P, Frantz S, Castoldi M, Muckenthaler M, Soutschek J, Koteliansky V, Rosenwald A, Bauersachs J*, Engelhardt S* (2008). MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 456, 980-984. *joint senior authors
  13. ↑ Bauersachs J, Thum T (2011). Biogenesis and regulation of cardiovascular microRNAs. Circ Res 109, 334-47.
  14. ↑ REBIRTH „From Regenerative Biology to Reconstructive Therapy“ (MHH)
  15. ↑ REBIRTH Cluster of Excellence
  16. ↑ Haghikia A, Podewski E, Berliner D, Sonnenschein K, Fischer D, Angermann CE, Böhm M, Röntgen P, Bauersachs J, Hilfiker-Kleiner D. Rationale and design of a randomized, controlled multicentre clinical trial to evaluate the effect of bromocriptine on left ventricular function in women with peripartum cardiomyopathy. Clin Res Cardiol. 2015 May 31.
  17. ↑ Hilfiker-Kleiner D, Haghikia A, Nonhoff J, Bauersachs J (2015). Peripartum cardiomyopathy: current management and future perspectives. Eur Heart J 36:1090-1097
  18. ↑ DIGitoxin to Improve ouTcomes in patients with advanced chronic systolic Heart Failure; EudraCT No: 2013-005326-38
  19. ↑ Heart Failure Association of the ESC
  20. ↑ DGIM
  21. ↑ ESAC Deutschland
  22. ↑ Aldosterone and mineralocorticoid receptor (ADMIRE)
  23. ↑ Hypertension
  24. ↑ Basic Research in Cardiology
  25. ↑ CRC
This article is issued from Wikipedia - version of the Monday, November 16, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.